European Journal of Clinical Pharmacology

, Volume 66, Issue 11, pp 1071–1079

Comparative efficacy and overall safety of different doses of consensus interferon for treatment of chronic HCV infection: a systematic review and meta-analysis

  • Seyed-Moayed Alavian
  • Bita Behnava
  • Seyed Vahid Tabatabaei
Review Article

Abstract

Background

About one-half of patients with hepatitis C genotype 1 and one-third with genotype 2/3 have treatment failure with peginterferon alpha and ribavirin. Consensus interferon (CIFN) is an option for retreatment of these patients.

Objective

To summarize comparative safety and efficacy of different regimens of CIFN for the treatment of patients with chronic hepatitis C infection.

Data source

Medline, Scopus, ISI, and Cochran Central Register of Clinical Trials were used.

Study eligibility criteria

Randomized clinical trials (RCTs) were eligible for inclusion in the study.

Participants

HIV and HBV seronegative patients with positive HCV-RNA during the 6 months before the start of the study were eligible for inclusion.

Interventions

Different regimens of CIFN were studied.

Study appraisal and synthesis methods

Studies were appraised based on methods of random sequence generation, allocation concealment, and blinding. The random effects model of DerSimonian and Laird was employed to run the meta-analysis. The end-point was sustained virological response (SVR).

Results

Data of 10 RCTs including 1,600 subjects were extracted. High daily induction dose regimen of CIFN did not yield a higher rate of SVR than low daily induction dose treatment regimen, RR = 0.83 (95% CI 0.58–1.17). A dose of 9 μg thrice weekly (tiw) was associated with a significantly higher rate of SVR compared with 3 μg [RR = 3.14 (95% CI 1.68–5.58)]‹. Withdrawal rate was similar [RR = 1.28 (95% CI 0.65–2.50)] but dose modification was higher in 9 μg [RR = 3.22 (95% CI 1.08–9.60)]. A dose of 18/15 μg tiw was not more effective than 9 μg over a similar treatment duration [RR = 1.02 (95% CI 0. 87–1.19)].

Limitations

Limitations include inadequate reporting of methodological information and side effects, lack of publication bias assessment due to the small number of studies in each analysis.

Conclusions

High dose daily induction therapy with CIFN is not superior to low dose therapy in terms of SVR. It seems that 9 μg tiw is the optimal treatment dose of CIFN for treatment of HCV infection. Optimal duration and safety profile of CIFN therapy have yet been elucidated.

Keywords

Consensus interferon Induction therapy High dose Low dose Meta-analysis Systematic review 

References

  1. 1.
    Ahmadipour MH, Alavian SM, Amini S, Azadmanesh K (2005) Hepatitis C virus genotypes. Hepat Mon 5(3):77–82Google Scholar
  2. 2.
    Arens M (2001) Clinically relevant sequence-based genotyping of HBV, HCV, CMV, and HIV. J Clin Virol 22(1):11–29CrossRefPubMedGoogle Scholar
  3. 3.
    Lavanchy D (2009) The global burden of hepatitis C. Liver Int 29(Suppl 1):74–81CrossRefPubMedGoogle Scholar
  4. 4.
    Seeff LB (2002) Natural history of chronic hepatitis C. Hepatology 36(5 Suppl 1):S35–S46CrossRefPubMedGoogle Scholar
  5. 5.
    Berenguer J, Alvarez-Pellicer J, Martin PM, Lopez-Aldeguer J, Von-Wichmann MA, Quereda C et al (2009) Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 50(2):407–413CrossRefPubMedGoogle Scholar
  6. 6.
    Singal AK, Singh A, Jaganmohan S, Guturu P, Mummadi R, Kuo YF et al (2010) Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol 8(2):192–199CrossRefPubMedGoogle Scholar
  7. 7.
    Breitenstein S, Dimitroulis D, Petrowsky H, Puhan MA, Mullhaupt B, Clavien PA (2009) Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis. Br J Surg 96(9):975–981CrossRefPubMedGoogle Scholar
  8. 8.
    Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z et al (2002) Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 122(5):1303–1313CrossRefPubMedGoogle Scholar
  9. 9.
    Miyake Y, Takaki A, Iwasaki Y, Yamamoto K (2010) Meta-analysis: interferon-alpha prevents the recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. J Viral Hepat 17(4):287–292Google Scholar
  10. 10.
    Poynard T, Leroy V, Mathurin P, Cohard M, Opolon P, Zarski JP (1996) Treatment of chronic hepatitis C by interferon for longer duration than six months. Dig Dis Sci 41(12 Suppl):99S–102SCrossRefPubMedGoogle Scholar
  11. 11.
    Hoofnagle JH, di Bisceglie AM (1997) The treatment of chronic viral hepatitis. N Engl J Med 336(5):347–356CrossRefPubMedGoogle Scholar
  12. 12.
    Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P et al (1996) Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 24(4):778–789CrossRefPubMedGoogle Scholar
  13. 13.
    Lin R, Roach E, Zimmerman M, Strasser S, Farrell GC (1995) Interferon alfa-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates. Results of the first multicentre Australian trial. Australia Hepatitis C Study Group. J Hepatol 23(5):487–496CrossRefPubMedGoogle Scholar
  14. 14.
    Carithers RL Jr, Emerson SS (1997) Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials. Hepatology 26(3 Suppl 1):83S–88SCrossRefPubMedGoogle Scholar
  15. 15.
    McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK et al (1998) Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 339(21):1485–1492CrossRefPubMedGoogle Scholar
  16. 16.
    Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G et al (1998) Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 352(9138):1426–1432CrossRefPubMedGoogle Scholar
  17. 17.
    Lai MY, Kao JH, Yang PM, Wang JT, Chen PJ, Chan KW et al (1996) Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterology 111(5):1307–1312CrossRefPubMedGoogle Scholar
  18. 18.
    Ferenci P, Formann E, Laferl H, Gschwantler M, Hackl F, Brunner H et al (2006) Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naive patients with chronic hepatitis C genotype 1 infection. J Hepatol 44(2):275–282CrossRefPubMedGoogle Scholar
  19. 19.
    Bosques-Padilla F, Trejo-Estrada R, Campollo-Rivas O, Cortez-Hernandez C, Dehesa-Violante M, Maldonado-Garza H et al (2003) Peginterferon alfa-2a plus ribavirin for treating chronic hepatitis C virus infection: analysis of Mexican patients included in a multicenter international clinical trial. Ann Hepatol 2(3):135–139PubMedGoogle Scholar
  20. 20.
    Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P et al (2004) Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140(5):346–355PubMedGoogle Scholar
  21. 21.
    Jacobson IM, Brown RS Jr, Freilich B, Afdhal N, Kwo PY, Santoro J et al (2007) Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology 46(4):971–981CrossRefPubMedGoogle Scholar
  22. 22.
    Gonzalez SA, Keeffe EB (2009) Management of chronic hepatitis C treatment failures: role of consensus interferon. Biologics 3:141–150PubMedGoogle Scholar
  23. 23.
    Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 151(4):W65–W94PubMedGoogle Scholar
  24. 24.
    Gluud LL (2006) Bias in clinical intervention research. Am J Epidemiol 163(6):493–501CrossRefPubMedGoogle Scholar
  25. 25.
    Bax L, Yu LM, Ikeda N, Tsuruta H, Moons KG (2006) Development and validation of MIX: comprehensive free software for meta-analysis of causal research data. BMC Med Res Methodol 6:50CrossRefPubMedGoogle Scholar
  26. 26.
    Borenstein M, Hedges LV, Higgins JPT, Rothstein HR (2009) Introduction to meta-analysis, 1st edn. Wiley, LondonGoogle Scholar
  27. 27.
    Petitti DB (2000) Meta-analysis, decision analysis, and cost-effectiveness analysis: methods for quantitative synthesis in medicine, 2nd edn. Oxford University Press, New YorkGoogle Scholar
  28. 28.
    Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557–560CrossRefPubMedGoogle Scholar
  29. 29.
    Alaimo G, Di Marco V, Ferraro D, Di Stefano R, Porrovecchio S, D'Angelo F et al (2006) Different doses of consensus interferon plus ribavirin in patients with hepatitis C virus genotype 1 relapsed after interferon monotherapy: a randomized controlled trial. World J Gastroenterol 12(42):6861–6864PubMedGoogle Scholar
  30. 30.
    Bocher WO, Schuchmann M, Link R, Hillenbrand H, Rahman F, Sprinzl M et al (2006) Consensus interferon and ribavirin for patients with chronic hepatitis C and failure of previous interferon-alpha therapy. Liver Int 26(3):319–325CrossRefPubMedGoogle Scholar
  31. 31.
    Cornberg M, Hadem J, Herrmann E, Schuppert F, Schmidt HH, Reiser M et al (2006) Treatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: a randomized open-label pilot study. J Hepatol 44(2):291–301CrossRefPubMedGoogle Scholar
  32. 32.
    Fattovich G, Zagni I, Minola E, Felder M, Rovere P, Carlotto A et al (2003) A randomized trial of consensus interferon in combination with ribavirin as initial treatment for chronic hepatitis C. J Hepatol 39(5):843–849CrossRefPubMedGoogle Scholar
  33. 33.
    Gaglio PJ, Rodriguez-Torres M, Herring R, Anand B, Box T, Rabinovitz M et al (2004) Racial differences in response rates to consensus interferon in HCV infected patients naive to previous therapy. J Clin Gastroenterol 38(7):599–604CrossRefPubMedGoogle Scholar
  34. 34.
    Heathcote EJ, James S, Mullen KD, Hauser SC, Rosenblate H, Albert DG Jr (1999) Chronic hepatitis C virus patients with breakthroughs during interferon treatment can successfully be retreated with consensus interferon. The Consensus Interferon Study Group. Hepatology 30(2):562–566CrossRefPubMedGoogle Scholar
  35. 35.
    Hirashima N, Orito E, Ohba K, Kondo H, Sakamoto T, Matsunaga S et al (2004) A randomized controlled trial of consensus interferon with or without lactoferrin for chronic hepatitis C patients with genotype 1b and high viral load. Hepatol Res 29(1):9–12CrossRefPubMedGoogle Scholar
  36. 36.
    Hwang SJ, Lee SD, Chan CY, Lu RH, Chang FY (1999) A randomized, double-blind, controlled trial of consensus interferon in the treatment of Chinese patients with chronic hepatitis C. Am J Gastroenterol 94(9):2496–2500CrossRefPubMedGoogle Scholar
  37. 37.
    Jensen DM, Krawitt EL, Keeffe EB, Hollinger FB, James SP, Mullen K et al (1999) Biochemical and viral response to consensus interferon (CIFN) therapy in chronic hepatitis C patients: effect of baseline viral concentration. Consensus Interferon Study Group. Am J Gastroenterol 94(12):3583–3588CrossRefPubMedGoogle Scholar
  38. 38.
    Kao JH, Chen PJ, Lai MY, Chen DS (2000) Efficacy of consensus interferon in the treatment of chronic hepatitis C. J Gastroenterol Hepatol 15(12):1418–1423CrossRefPubMedGoogle Scholar
  39. 39.
    Keeffe EB, Dusheiko GM, James SP, Mullen KD, Everson GT, Pimstone NR et al (1999) Utility of hepatitis C virus serotypes in predicting response to treatment of chronic hepatitis C. Consensus Interferon Study Group. Cytokines Cell Mol Ther 5(4):207–210PubMedGoogle Scholar
  40. 40.
    Keeffe EB, Dusheiko GM, Tong MJ, Hollinger FB, Heathcote EJ, McHutchison J et al (1999) Genotype does not affect pattern of HCV RNA decrease among responders during interferon treatment of chronic hepatitis C. Consensus Interferon Study Group. Cytokines Cell Mol Ther 5(4):211–216PubMedGoogle Scholar
  41. 41.
    Layden TJ, Layden JE, Reddy KR, Levy-Drummer RS, Poulakos J, Neumann AU (2002) Induction therapy with consensus interferon (CIFN) does not improve sustained virologic response in chronic hepatitis C. J Viral Hepat 9(5):334–339CrossRefPubMedGoogle Scholar
  42. 42.
    Miglioresi L, Bacosi M, Russo F, Patrizi F, Saccenti P, Ursitti A et al (2003) Consensus interferon versus interferon-α 2b plus ribavirin in patients with relapsing HCV infection. Hepatol Res 27(4):253–259CrossRefPubMedGoogle Scholar
  43. 43.
    Pockros PJ, Reindollar R, McHutchinson J, Reddy R, Wright T, Boyd DG et al (2003) The safety and tolerability of daily infergen plus ribavirin in the treatment of naive chronic hepatitis C patients. J Viral Hepat 10(1):55–60CrossRefPubMedGoogle Scholar
  44. 44.
    Pockros PJ, Tong M, Lee WM, van Leeuwen DJ, Keeffe EB, Bala K et al (1998) Relationship between biochemical and virological responses to interferon therapy in chronic hepatitis C infection. Consensus Interferon Study Group. J Viral Hepat 5(4):271–276CrossRefPubMedGoogle Scholar
  45. 45.
    Reddy KR, Hoofnagle JH, Tong MJ, Lee WM, Pockros P, Heathcote EJ et al (1999) Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group. Hepatology 30(3):787–793CrossRefPubMedGoogle Scholar
  46. 46.
    Saito H, Tada S, Ebinuma H, Ishii H, Kashiwazaki K, Nishida J et al (2006) Induction therapy with twice-daily interferon-beta does not improve the therapeutic efficacy of consensus interferon monotherapy for chronic hepatitis C. Keio J Med 55(3):111–117CrossRefPubMedGoogle Scholar
  47. 47.
    Sjogren MH, Sjogren R, Holtzmuller K, Winston B, Butterfield B, Drake S et al (2005) Interferon alfacon-1 and ribavirin versus interferon alpha-2b and ribavirin in the treatment of chronic hepatitis C. Dig Dis Sci 50(4):727–732CrossRefPubMedGoogle Scholar
  48. 48.
    Sjogren MH, Sjogren R Jr, Lyons MF, Ryan M, Santoro J, Smith C et al (2007) Antiviral response of HCV genotype 1 to consensus interferon and ribavirin versus pegylated interferon and ribavirin. Dig Dis Sci 52(6):1540–1547CrossRefPubMedGoogle Scholar
  49. 49.
    Suzuki H, Sato K, Takagi H, Kanda D, Sohara N, Kakizaki S et al (2006) Randomized controlled trial of consensus interferon with or without zinc for chronic hepatitis C patients with genotype 2. World J Gastroenterol 12(6):945–950PubMedGoogle Scholar
  50. 50.
    Suzuki H, Tango T (2002) A multicenter, randomized, controlled clinical trial of interferon alfacon-1 in comparison with lymphoblastoid interferon-alpha in patients with high-titer chronic hepatitis C virus infection. Hepatol Res 22(1):1–12CrossRefPubMedGoogle Scholar
  51. 51.
    Tong MJ, Reddy KR, Lee WM, Pockros PJ, Hoefs JC, Keeffe EB et al (1997) Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group. Hepatology 26(3):747–754CrossRefPubMedGoogle Scholar
  52. 52.
    Yao GB, Fu XX, Tian GS, Xu DZ, Hao LJ, Huangfu YS et al (2000) A multicenter, randomized, controlled trial of interferon alfacon-1 compared with alpha-2a-interferon in Chinese patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol 15(10):1165–1170CrossRefPubMedGoogle Scholar
  53. 53.
    MacNicholas R, Norris S (2010) Review article: optimizing SVR and management of the haematological side effects of peginterferon/ribavirin antiviral therapy for HCV—the role of epoetin, G-CSF and novel agents. Aliment Pharmacol Ther 31(9):929–937Google Scholar
  54. 54.
    Kraus MR, Schafer A, Schottker K, Keicher C, Weissbrich B, Hofbauer I et al (2008) Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study. Gut 57(4):531–536CrossRefPubMedGoogle Scholar
  55. 55.
    Hopewell S, Loudon K, Clarke MJ, Oxman AD, Dickersin K (2009) Publication bias in clinical trials due to statistical significance or direction of trial results. Cochrane Database Syst Rev (1):MR000006Google Scholar
  56. 56.
    Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R (2008) Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 358(3):252–260CrossRefPubMedGoogle Scholar
  57. 57.
    Moher D, Jones A, Lepage L (2001) Use of the CONSORT statement and quality of reports of randomized trials: a comparative before-and-after evaluation. JAMA 285(15):1992–1995CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Seyed-Moayed Alavian
    • 1
  • Bita Behnava
    • 1
  • Seyed Vahid Tabatabaei
    • 1
  1. 1.Baqiyatallah Research Center for Gastroenterology and Liver DiseaseBaqiyatallah University of Medical SciencesTehranIran

Personalised recommendations